These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 9367823

  • 1. Geldanamycin-induced destabilization of Raf-1 involves the proteasome.
    Schulte TW, An WG, Neckers LM.
    Biochem Biophys Res Commun; 1997 Oct 29; 239(3):655-9. PubMed ID: 9367823
    [Abstract] [Full Text] [Related]

  • 2. CYP2E1 degradation by in vitro reconstituted systems: role of the molecular chaperone hsp90.
    Goasduff T, Cederbaum AI.
    Arch Biochem Biophys; 2000 Jul 15; 379(2):321-30. PubMed ID: 10898951
    [Abstract] [Full Text] [Related]

  • 3. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo.
    Whitesell L, Sutphin P, An WG, Schulte T, Blagosklonny MV, Neckers L.
    Oncogene; 1997 Jun 12; 14(23):2809-16. PubMed ID: 9190897
    [Abstract] [Full Text] [Related]

  • 4. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway.
    Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM.
    Mol Cell Biol; 1996 Oct 12; 16(10):5839-45. PubMed ID: 8816498
    [Abstract] [Full Text] [Related]

  • 5. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.
    Nimmanapalli R, O'Bryan E, Bhalla K.
    Cancer Res; 2001 Mar 01; 61(5):1799-804. PubMed ID: 11280726
    [Abstract] [Full Text] [Related]

  • 6. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome.
    An WG, Schulte TW, Neckers LM.
    Cell Growth Differ; 2000 Jul 01; 11(7):355-60. PubMed ID: 10939589
    [Abstract] [Full Text] [Related]

  • 7. Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells.
    Vasilevskaya IA, O'Dwyer PJ.
    Cancer Res; 1999 Aug 15; 59(16):3935-40. PubMed ID: 10463587
    [Abstract] [Full Text] [Related]

  • 8. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
    Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, Garcia de Herreros A, Dunach M, Neckers LM.
    Cancer Res; 2001 Feb 15; 61(4):1671-7. PubMed ID: 11245482
    [Abstract] [Full Text] [Related]

  • 9. The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.
    Schnaider T, Somogyi J, Csermely P, Szamel M.
    Cell Stress Chaperones; 2000 Jan 15; 5(1):52-61. PubMed ID: 10701840
    [Abstract] [Full Text] [Related]

  • 10. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
    Schulte TW, Neckers LM.
    Cancer Chemother Pharmacol; 1998 Jan 15; 42(4):273-9. PubMed ID: 9744771
    [Abstract] [Full Text] [Related]

  • 11. Cell adhesion protects c-Raf-1 against ubiquitin-dependent degradation by the proteasome.
    Manenti S, Delmas C, Darbon JM.
    Biochem Biophys Res Commun; 2002 Jun 28; 294(5):976-80. PubMed ID: 12074572
    [Abstract] [Full Text] [Related]

  • 12. The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase.
    Ochel HJ, Schulte TW, Nguyen P, Trepel J, Neckers L.
    Mol Genet Metab; 1999 Jan 28; 66(1):24-30. PubMed ID: 9973544
    [Abstract] [Full Text] [Related]

  • 13. [Ligand-induced polyubiquitination of receptor tyrosine kinases].
    Mori S.
    Tanpakushitsu Kakusan Koso; 1997 Oct 28; 42(14 Suppl):2284-90. PubMed ID: 9366209
    [No Abstract] [Full Text] [Related]

  • 14. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association.
    Nagata Y, Anan T, Yoshida T, Mizukami T, Taya Y, Fujiwara T, Kato H, Saya H, Nakao M.
    Oncogene; 1999 Oct 28; 18(44):6037-49. PubMed ID: 10557093
    [Abstract] [Full Text] [Related]

  • 15. Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases.
    Yorgin PD, Hartson SD, Fellah AM, Scroggins BT, Huang W, Katsanis E, Couchman JM, Matts RL, Whitesell L.
    J Immunol; 2000 Mar 15; 164(6):2915-23. PubMed ID: 10706677
    [Abstract] [Full Text] [Related]

  • 16. Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway.
    Lawson B, Brewer JW, Hendershot LM.
    J Cell Physiol; 1998 Feb 15; 174(2):170-8. PubMed ID: 9428803
    [Abstract] [Full Text] [Related]

  • 17. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L.
    Clin Cancer Res; 2003 Oct 15; 9(13):4961-71. PubMed ID: 14581371
    [Abstract] [Full Text] [Related]

  • 18. Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells.
    Kim HR, Kang HS, Kim HD.
    IUBMB Life; 1999 Oct 15; 48(4):429-33. PubMed ID: 10632574
    [Abstract] [Full Text] [Related]

  • 19. p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function.
    Grammatikakis N, Lin JH, Grammatikakis A, Tsichlis PN, Cochran BH.
    Mol Cell Biol; 1999 Mar 15; 19(3):1661-72. PubMed ID: 10022854
    [Abstract] [Full Text] [Related]

  • 20. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D.
    Cancer Res; 2003 Dec 15; 63(24):8984-95. PubMed ID: 14695217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.